-
Axicabtagene ciloleucel, sold
under the
brand name Yescarta, is a
medication used for the
treatment for
large B-cell
lymphoma that has
failed conventional...
- B-cell
precursor acute lymphoblastic leukemia (B-ALL), and
axicabtagene ciloleucel (Yescarta),
marketed by Kite
Pharma originally for
diffuse large B-cell...
-
annual list of the
preceding year's 50
Smartest Companies.
Axicabtagene ciloleucel (KTE-C19, ZUMA-3, YESCARTA) was an
investigational therapy (for the treatment...
-
large B-cell
lymphoma with two
failed systemic treatments),
axicabtagene ciloleucel,
tisagenlecleucel (for
large B-cell lymphoma), and
brexucabtagene autoleucel...
-
trioxide Asparagine depleters (Asparaginase#/Pegaspargase)
Axicabtagene ciloleucel Belzutifan Bexarotene Brexucabtagene autoleucel Celecoxib Ciltacabtagene...
-
trioxide Asparagine depleters (Asparaginase#/Pegaspargase)
Axicabtagene ciloleucel Belzutifan Bexarotene Brexucabtagene autoleucel Celecoxib Ciltacabtagene...
- to
those of the REMS
Program for
another CAR-T therapy,
axicabtagene ciloleucel (Yescarta).
Brexucabtagene autoleucel was
approved for
medical use in...
-
trioxide Asparagine depleters (Asparaginase#/Pegaspargase)
Axicabtagene ciloleucel Belzutifan Bexarotene Brexucabtagene autoleucel Celecoxib Ciltacabtagene...
-
treating refractory and
relapsed DLBCL, NOS (tisagenlecleucel,
axicabtagene ciloleucel,
lisocabtagene maraleucel).
Chimeric antigen receptor T
cells are genetically...
- the
United States. In October, a
similar therapy called axicabtagene ciloleucel was
approved for non-Hodgkin lymphoma. In October,
biophysicist and biohacker...
